Pembrolizumab is a humanized monoclonal antibody of the IgG4 isotype with a high affinity for PD-1, whose mechanism of action is based on blocking the interaction between the PD-1 receptor on T cells and the PD-L1 ligand on tumor cells. This evidence concerns the gene PDCD1 and neoplasm.